Cavagna F, Daprà M, Maggioni F, de Haën C, Felder E
Research and Development Division, Bracco Industria Chimica SpA, Milan, Italy.
Magn Reson Med. 1991 Dec;22(2):329-33; discussion 343-6. doi: 10.1002/mrm.1910220235.
The novel tissue-specific contrast agent, Gd-BOPTA/Dimeg, was tested in MR imaging of experimental focal liver disease and of acute myocardial ischemia in rats. Directly implanted liver tumors and blood-borne metastases were used as models for focal liver disease and occlusion of the lower anterior descending coronary artery as model for acute ischemia. The studies with implanted tumors, at a dose level of 250 mumol/kg, showed a very high (370%) and persistent (greater than 2 h) increase in the tumor-liver contrast-to-noise ratio (CNR), owing to selective enhancement of normal liver parenchyma signal intensity. While all blood-borne metastases showed a similar late CNR enhancement, some of them experienced early contrast loss due to transient signal intensity enhancement. In myocardial imaging, Gd-BOPTA/Dimeg produced a signal intensity enhancement in normal myocardium and an injured area-normal area CNR enhancement which were both much stronger and more persistent than those produced by Gd-DTPA/Dimeg.
新型组织特异性造影剂钆布醇/二甲基葡胺（Gd-BOPTA/Dimeg）在大鼠实验性局灶性肝病和急性心肌缺血的磁共振成像中进行了测试。直接植入的肝肿瘤和血行转移瘤被用作局灶性肝病的模型，而结扎下前降支冠状动脉被用作急性缺血的模型。在植入肿瘤的研究中，剂量水平为250 μmol/kg时，由于正常肝实质信号强度的选择性增强，肿瘤-肝脏对比噪声比（CNR）出现了非常高（370%）且持续（超过2小时）的增加。虽然所有血行转移瘤都显示出类似的晚期CNR增强，但其中一些由于短暂的信号强度增强而出现早期对比剂丢失。在心肌成像中，钆布醇/二甲基葡胺在正常心肌中产生的信号强度增强以及梗死区与正常区的CNR增强，都比钆喷酸葡胺/二甲基葡胺（Gd-DTPA/Dimeg）产生的更强且更持久。
